Anti-Human CD116 Monoclonal Antibody () for Flow Cytometry - P15509

Core Product Specifications and Parameters

Biological Background: Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Function and Localization

• The protein is the granulocyte-macrophage colony-stimulating factor receptor subunit alpha (GM-CSF-R-alpha), also known as CDw116, encoded by the CSF2RA gene (aliases CSF2R, CSF2RY) in humans.
• It functions as a low-affinity receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF), transducing signals that lead to the proliferation, differentiation, and functional activation of hematopoietic cells.
• The receptor belongs to the type I cytokine receptor family and is essential for myeloid lineage development and immune responses.
• Subcellularly, it is found at the cell membrane and can also exist as secreted isoforms due to alternative splicing.
• Key structural features include a signal peptide, a transmembrane helix, disulfide bonds, and glycosylation sites.
• The protein is implicated in certain disease variants and has been identified in proteomics studies.

Experimental Guidance and Technical Tips

• This antibody is designed for flow cytometry (FC) and is conjugated to ; consider optimizing the titration for your specific cell type.
• As a rabbit monoclonal antibody, it may offer high specificity and lot-to-lot consistency; always include proper isotype controls in your FC experiments.
• The immunogen covers amino acids 23–320, which includes the extracellular domain; therefore, the antibody is expected to recognize the extracellular region of CD116.
• Validate the antibody’s reactivity in your sample system, particularly in human hematopoietic or myeloid-derived cell lines known to express CSF2RA.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio connects diagnostic manufacturers and research labs with high-quality IVD raw materials, including this anti-human CD116 monoclonal antibody for hematopoietic and immunological applications. We offer validated antibody pairs, optimized monoclonal/polyclonal antibodies, bulk ancillary reagents, and sourcing support for rare targets to streamline your development from concept to clinic.